Goldman Sachs, 2018: 'Is Curing Patients a Sustainable Business Model?'
catherinesalgado.substack.com
This question was asked by Goldman Sachs analysts in April of 2018, according to CNBC: “Is curing patients a sustainable business model?” “Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering ‘gene therapy’ treatment: cures could be bad for business in the long run.
Goldman Sachs, 2018: 'Is Curing Patients a Sustainable Business Model?'
Goldman Sachs, 2018: 'Is Curing Patients a…
Goldman Sachs, 2018: 'Is Curing Patients a Sustainable Business Model?'
This question was asked by Goldman Sachs analysts in April of 2018, according to CNBC: “Is curing patients a sustainable business model?” “Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering ‘gene therapy’ treatment: cures could be bad for business in the long run.